FDA approves Seroquel for bipolar maintenance

The FDA has approved AstraZeneca’s Seroquel (quetiapine fumarate tablets) for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex. Clinical trial results indicated that patients treated with Seroquel plus lithium or divalproex had a 70% risk reduction relative to those treated with placebo plus lithium or divalproex for time to recurrence of a depressive, manic, or mixed mood event.

Seroquel is already indicated for the treatment of schizophrenia, depressive episodes in bipolar disorder, and acute mania in bipolar I disorder.

For more information call (800) 236-9933 or visit www.seroquel.com.